News Breaks |
|
|
| February 3, 2013 |
| 14:25 EDT |  | RHHBY, BSX, MDT, MRK, LLY, BMY, PFE, SNY, AZN, GSK, JNJ, STJ | Drug, medical device makers must disclose doctor payments, Bloomberg says
Payments from drugmakers and medical device companies to doctors must be disclosed to the U.S. government beginning next March, says Bloomberg. Reference Link |
|
|
News For RHHBY;JNJ;GSK;AZN;SNY;PFE;BMY;LLY;MRK;MDT;BSX;STJ From The Last 14 Days Check below for free stories on RHHBY;JNJ;GSK;AZN;SNY;PFE;BMY;LLY;MRK;MDT;BSX;STJ the last two weeks. |
|
|
| May 22, 2013 |
| 18:52 EDT |  | MRK | On The Fly: After Hours Movers
UP AFTER EARNINGS: Hewlett-Packard (HPQ), up 13.4% after reporting second quarter earnings that beat expectations and guiding third quarter and full-year earnings above estimates... Pacific Sunwear (PSUN), up 14.3%. ALSO HIGHER: Merck (MRK), up 0.2% after an FDA advisory panel voted 13-3 in support of the safety of initial doses of its insomnia drug suvorexant. DOWN AFTER EARNINGS: DryShips (DRYS), down 4.7%. ALSO LOWER: Apricus Biosciences (APRI), down 11.5% after filing to sell an ungiven amount of stock... NCI Building Systems (NCS) after being replaced by Cynosure (CYNO) in the S&P 600 as of May 31. |
|
| 18:32 EDT | | MRK | Merck's suvorexant for insomnia reviewed by FDA advisory committee
 Subscribe for More Information |
|
| 18:06 EDT | | MRK | Merck insomnia drug gets FDA panel backing, WSJ reports
Merck's insomnia drug suvorexant received a favorable 13-3 vote from an FDA panel on the drug's two proposed starting doses, with the panel splitting the vote on the safety of higher doses, reports the Wall Street Journal. Reference Link |
|
| 16:16 EDT | | MRK | FDA panel votes 13-3 that Merck insomnia drug safe in low doses, Bloomberg says
Subscribe for More Information |
|
| 16:00 EDT |  | JNJ, BMY, MRK | Options Update; May 22, 2013
Subscribe for More Information |
|
| 14:52 EDT | | MRK | FDA panel says Merck insomnia drug effective as sleep aid, Bloomberg reports
Subscribe for More Information |
|
| 12:22 EDT | | BSX | Boston Scientific says new data shows blood pressure reduction with Vessix
Boston Scientific reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and sustained reduction in the blood pressure of patients treated with the Vessix Renal Denervation System. Data on the first 41 subjects enrolled in the REDUCE-HTN clinical program were presented at the annual EuroPCR Scientific Program in Paris. Interim data highlights include: All patients underwent successful bilateral renal denervation treatment; At the primary endpoint of six months, patients experienced a significant 27.6 mmHg reduction in systolic blood pressure; No device-related adverse events or procedural renal artery complications were reported; Long term efficacy was demonstrated, with a sustained 28.4 mmHg reduction in systolic blood pressure in the subset of patients for whom 12-month data are available; Demonstrated success in treating various anatomies, including accessory renal arteries; Demonstrated short renal denervation procedural time. |
|
| 10:44 EDT | | BSX | Boston Scientific says Lotus system met primary performance endpoint in trial
Subscribe for More Information |
|
| 10:33 EDT | | BMY, RHHBY | Bristol-Myers jumps after Citi ups rating on cancer potential
Subscribe for More Information |
|
| 10:16 EDT |  | BMY | Bristol-Myers spikes higher following upgrade, levels to watch
Subscribe for More Information |
| |
| 10:00 EDT |  | RHHBY, BMY | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 09:39 EDT | | MRK | Active equity option families trading
Subscribe for More Information |
|
| 09:35 EDT | | BSX | Boston Scientific says trials show 'exceptional' safety, efficacy data on stents
Boston Scientific reported positive results from two trials evaluating new, innovative drug-eluting stent technologies, which are emerging treatment options for coronary heart disease. Data from the first human use NG PROMUS Clinical Trial evaluating the safety and effectiveness of the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System, and two-year follow-up data from the EVOLVE Trial comparing the safety and effectiveness of the SYNERGY Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary Stent System to the PROMUS Element Stent System were presented at the annual EuroPCR Scientific Program in Paris. The primary investigator for one trial said, "The Promus PREMIER Stent demonstrated excellent safety and effectiveness with zero percent target lesion revascularization and stent thrombosis. In addition, the rate of technical success, the primary endpoint of the trial, was very high at 99.2%." |
|
| 09:01 EDT | | AZN | Par Pharmaceutical begins shipment of generic Atacand
Subscribe for More Information |
|
| 08:59 EDT | | PFE | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 08:25 EDT | | GSK | GlaxoSmithKline awarded up to $200M by U.S. to develop new antibiotics
Subscribe for More Information |
|
| 08:06 EDT | | PFE | Zoetis comments on Pfizer’s split-off plans for remaining interest
Subscribe for More Information |
|
| 08:04 EDT | | PFE | Pfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information |
|
| 08:02 EDT | | PFE | Pfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information |
|
| 07:48 EDT |  | MDT | FDA Orthopaedic and Rehabilitation Devices Panel to hold a meeting
Subscribe for More Information |
| |
|
|
|
|
